Understanding How to Best Measure MRD Negativity in Ph+ ALL
The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.
Tumor Lysis Syndrome: Unmet Needs and Future Directions in Care
Closing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.
TLS Management in Academic vs Community Centers of Care
A brief review of the differences that might be observed between tumor lysis syndrome management in an academic versus community setting.
Tumor Lysis Syndrome: Clinical Implications of Prophylaxis and Treatment
Experts James Short, MD, and John Reagan, MD, share comprehensive insight on the clinical implications of treating TLS in patients receiving therapy for cancer.
Guideline-Directed Treatment Options for Tumor Lysis Syndrome
James Short, MD, and John Reagan, MD, highlight guideline-indicated treatment options for patients with or at risk of tumor lysis syndrome.
Prophylactic Measures to Prevent Tumor Lysis Syndrome
Expert perspectives on prophylactic measures to prevent tumor lysis syndrome in patients receiving therapy for cancer.
Role of a Multidisciplinary Healthcare Team to Manage Tumor Lysis Syndrome
Shared insight on the multidisciplinary management of tumor lysis syndrome and how treatment planning may be adjusted after it is identified.
Identification of Tumor Lysis Syndrome: Signs and Symptoms
Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.
Overview on Tumor Lysis Syndrome: Incidence and Risk Factors
Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.
Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.
Dr. Short on Ponatinib and Blinatumomab in Philadelphia Chromosome–Positive ALL
Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL
Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.
Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer
Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC
Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS
2 Clarke Drive Cranbury, NJ 08512